Gem Aromatics flags phenol cost pressure as Dahej expansion starts
Standalone Q4 operating margin was 13.41%, while management said the Dahej ramp-up and planned Rs 270 cr investment will support future growth.
Filed 28 Jul 2026, 17:59 IST · after market close · GEMAROMA (GEMAROMA)
Key takeaways
- Standalone Q4FY26 revenue of Rs 112.24 cr produced an operating margin of 13.41% and net profit of Rs 11.87 cr.
- Management said the Dahej ramp-up is expected to support utilization and future growth, alongside planned investment of approximately Rs 270 cr.
- Phenol price volatility and higher depreciation after Dahej capex capitalization weighed on profitability despite better volumes and price realization, management said.
Q4 profit reflected both operating pressure and non-operating support
Standalone Q4FY26 revenue of Rs 112.24 cr translated into Rs 15.05 cr of operating profit and Rs 11.87 cr of net profit. Other income of Rs 3.83 cr supplemented operating profit, while interest of Rs 1.52 cr, depreciation of Rs 1.39 cr and tax of Rs 4.12 cr reduced the conversion to net profit.
Phenol volatility and Dahej depreciation weighed on the 13.41% margin
Management said geopolitical issues disrupted phenol availability, causing sharp raw-material price increases and volatility in production timelines for phenol derivatives. The company also said profitability was affected by higher depreciation after Dahej capex was capitalized. Management nevertheless reported better volumes and price realization as domestic and global demand gradually recovered in Q4FY26.
Dahej adds new products while the company broadens its chemistry portfolio
Commercial production of GEM Cool 5 cooling agents and Safranal commenced at Dahej on 26 February 2026, management said. The company has planned approximately Rs 270 cr of Dahej investment through internal accruals and debt, and management said the facility ramp-up is expected to support utilization and future growth. The presentation also describes a move into phenolic products for pharma, antioxidant and fragrance applications.
Results were filed after market close
The results were filed after market close on 28 July 2026. The filing timing means the immediate stock-market response is not yet part of the quarter's read-through.
Q4FY26 at a glance
Standalone figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q4FY26 |
|---|---|
| Revenue | ₹112 cr |
| Other income | ₹4 cr |
| Expenses | ₹97 cr |
| Operating profit | ₹15 cr |
| Operating margin (%) | 13.41% |
| Interest | ₹2 cr |
| Depreciation | ₹1 cr |
| Profit before tax | ₹16 cr |
| Tax | ₹4 cr |
| Net profit | ₹12 cr |
| EPS (₹) | ₹2.33 |
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- Q4FY26 saw gradual recovery in domestic and global demand, with better volumes and price realization.
- Commercial production of GEM Cool 5 and Safranal commenced on 26 February 2026.
Guidance & outlook
- The Dahej facility ramp-up is expected to support utilization and future growth.
Expansion
- The company has planned approximately Rs 270 crore of Dahej investment through internal accruals and debt.
- Commercial production of GEM Cool 5 cooling agents and Safranal commenced during Q4 FY26.
New products
- The company commenced commercial production of GEM Cool 5 cooling agents and Safranal at Dahej.
New initiatives
- The company is entering advanced chemistry with a diversified phenolic portfolio for pharma, antioxidant and fragrance applications.
Competition
- The company describes its forward-integrated phenol processes as enabling entry into limited-competition, high-margin molecules.
- The company states that it is one of the largest processors of Clove Oil and Eugenol by volume in India for FY25.
Problems & risks
- Geopolitical issues have affected phenol availability, causing significant price volatility and sharply higher raw material prices.
- Higher phenol prices and supply volatility continue to affect near-term production timelines for phenol derivatives.
- Profitability was affected by higher depreciation after capitalization of Dahej capex.
What to watch
- Whether standalone operating margin holds above 13.41% as phenol prices and supply volatility remain in focus.
- Progress in Dahej ramp-up against the planned approximately Rs 270 cr investment.
- Volumes and price realization from GEM Cool 5 and Safranal after commercial production began on 26 February 2026.